NASDAQ:ONCT - Oncternal Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.50
  • Forecasted Upside: 168.52 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$5.40
▼ -0.01 (-0.18%)
1 month | 3 months | 12 months
Get New Oncternal Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ONCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ONCT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$14.50
▲ +168.52% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Oncternal Therapeutics in the last 3 months. The average price target is $14.50, with a high forecast of $21.00 and a low forecast of $8.00. The average price target represents a 168.52% upside from the last price of $5.40.
Buy
The current consensus among 2 investment analysts is to buy stock in Oncternal Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/15/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/14/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2021Northland SecuritiesInitiated CoverageOutperform$21.00High
i
11/12/2020HC WainwrightReiterated RatingBuyLow
i
Rating by R. Selvaraju at HC Wainwright
9/21/2020HC WainwrightReiterated RatingBuy$8.00Low
i
Rating by R. Selvaraju at HC Wainwright
8/10/2020HC WainwrightInitiated CoverageBuy$8.00Medium
i
Rating by R. Selvaraju at HC Wainwright
(Data available from 3/9/2016 forward)
Oncternal Therapeutics logo
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. The company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ROR1) that is in Phase I/II clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in Phase Ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. It also develops TK-216, a small-molecule that is designed to inhibit E26 transformation specific family of oncoproteins, which is in Phase I clinical trial to treat patients with Ewing sarcoma and in combination with vincristine chemotherapy. In addition, the company develops a chimeric antigen receptor-T product candidate that targets ROR1, which is in preclinical development for treating hematologic cancers and solid tumors. Oncternal Therapeutics, Inc. has a research and development collaboration with Karolinska Institutet to advance novel ROR1-targeting cell therapies focused on CAR-T cells and CAR-NK cells. The company is headquartered in San Diego, California.
Read More

Today's Range

Now: $5.40
$5.31
$5.86

50 Day Range

MA: $6.45
$5.19
$8.31

52 Week Range

Now: $5.40
$1.49
$8.65

Volume

790,912 shs

Average Volume

1,585,673 shs

Market Capitalization

$210.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Oncternal Therapeutics?

The following equities research analysts have issued stock ratings on Oncternal Therapeutics in the last year: HC Wainwright, Northland Securities, and Zacks Investment Research.
View the latest analyst ratings for ONCT.

What is the current price target for Oncternal Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Oncternal Therapeutics in the last year. Their average twelve-month price target is $14.50, suggesting a possible upside of 168.5%. Northland Securities has the highest price target set, predicting ONCT will reach $21.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $8.00 for Oncternal Therapeutics in the next year.
View the latest price targets for ONCT.

What is the current consensus analyst rating for Oncternal Therapeutics?

Oncternal Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ONCT will outperform the market and that investors should add to their positions of Oncternal Therapeutics.
View the latest ratings for ONCT.

What other companies compete with Oncternal Therapeutics?

How do I contact Oncternal Therapeutics' investor relations team?

Oncternal Therapeutics' physical mailing address is 12230 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company's listed phone number is 858-434-1113 and its investor relations email address is [email protected] The official website for Oncternal Therapeutics is www.oncternal.com.